Insights

Expanding Patents Longeveron holds multiple patents across the US, Canada, and Japan for its mesenchymal stem cell therapies and methods, indicating strong intellectual property protections that support potential licensing deals or partnerships in international markets.

Regenerative Focus The company's emphasis on cellular therapies for aging-related conditions and rare pediatric diseases presents opportunities to position their innovative treatments to healthcare providers specializing in geriatrics, neurology, and pediatric cardiology.

Strategic Incentives Recognition by regulators such as the FDA with orphan, rare pediatric disease, and fast-track designations for laromestrocel can facilitate faster approval processes, opening avenues to expedite market entry and sales in the U.S. and collaborate with payers focused on unmet medical needs.

Recent Advancements Longeveron’s recent patent grants and positive clinical trial momentum, including pivotal Phase 2b results anticipated in 2026, highlight their growing credibility and potential readiness for commercialization in select indications, encouraging early partnership or distribution opportunities.

Market Positioning With a focus on aging-related conditions and pediatric diseases, Longeveron can tailor sales strategies toward specialized clinics, geriatric centers, and pediatric healthcare providers that target unmet needs in aging and rare diseases, creating opportunities for early adoption and collaborative development.

Longeveron Tech Stack

Longeveron uses 8 technology products and services including Fastly, Wix, WordPress, and more. Explore Longeveron's tech stack below.

  • Fastly
    Content Delivery Network
  • Wix
    Content Management System
  • WordPress
    Content Management System
  • oEmbed
    Dev Tools
  • Twemoji
    Font Scripts
  • Google Fonts API
    Font Scripts
  • RequireJS
    Javascript Frameworks
  • Microsoft ASP.NET
    Web Frameworks

Media & News

Longeveron's Email Address Formats

Longeveron uses at least 1 format(s):
Longeveron Email FormatsExamplePercentage
FLast@longeveron.comJDoe@longeveron.com
48%
First@longeveron.comJohn@longeveron.com
2%
FLast@longeveron.comJDoe@longeveron.com
48%
First@longeveron.comJohn@longeveron.com
2%

Frequently Asked Questions

What is Longeveron's phone number?

Minus sign iconPlus sign icon
You can contact Longeveron's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Longeveron's stock symbol?

Minus sign iconPlus sign icon
Longeveron is a publicly traded company; the company's stock symbol is LGVN.

What is Longeveron's official website and social media links?

Minus sign iconPlus sign icon
Longeveron's official website is longeveron.com and has social profiles on LinkedIn.

What is Longeveron's SIC code NAICS code?

Minus sign iconPlus sign icon
Longeveron's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Longeveron have currently?

Minus sign iconPlus sign icon
As of February 2026, Longeveron has approximately 40 employees across 2 continents, including North AmericaEurope. Key team members include Chief Medical Officer: N. A.Chief Technology Officer: D. B.Vice President Of Technical Operations: J. L.. Explore Longeveron's employee directory with LeadIQ.

What industry does Longeveron belong to?

Minus sign iconPlus sign icon
Longeveron operates in the Biotechnology Research industry.

What technology does Longeveron use?

Minus sign iconPlus sign icon
Longeveron's tech stack includes FastlyWixWordPressoEmbedTwemojiGoogle Fonts APIRequireJSMicrosoft ASP.NET.

What is Longeveron's email format?

Minus sign iconPlus sign icon
Longeveron's email format typically follows the pattern of FLast@longeveron.com. Find more Longeveron email formats with LeadIQ.

How much funding has Longeveron raised to date?

Minus sign iconPlus sign icon
As of February 2026, Longeveron has raised $4.6M in funding. .

When was Longeveron founded?

Minus sign iconPlus sign icon
Longeveron was founded in 2014.

Longeveron

Biotechnology ResearchFlorida, United States11-50 Employees

We are a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions. Our lead investigational product is laromestrocel (Lomecel-B™), which is derived from culture-expanded mesenchymal stem cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult diseases and conditions associated with aging.
Our clinical development programs have delivered several positive initial results across 5 clinical trials in 3 indications:  Phase 1 & 2 in Alzheimer’s Disease, Phase 1 & 2 in Aging-related Frailty, Phase 1 in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease.  We are currently conducting a pivotal Phase2b clinical trial in HLHS. Our mission is to advance laromestrocel (Lomecel-B™) and other cell-based product candidates into pivotal trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.
Our philosophy is that healthy aging can be improved through regenerative medicine approaches. Life expectancy has substantially increased over the past century as a result of medical and public health advancements. However, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging – a period known as healthspan. As we age, we experience a profound decline, in both number and function, in our own MSCs, a decrease in immune system function, decline in blood vessel functioning, chronic inflammation and other issues. Our clinical data suggest that laromestrocel (Lomecel-B™) addresses these conditions through multiple mechanisms of action, or MOAs, that target key aging-related processes

Section iconCompany Overview

Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
LGVN
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2014
Employees
11-50

Section iconFunding & Financials

  • $4.6M

    Longeveron has raised a total of $4.6M of funding over 2 rounds. .

  • $1M

    Longeveron's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $4.6M

    Longeveron has raised a total of $4.6M of funding over 2 rounds. .

  • $1M

    Longeveron's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.